Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI110472

Cytosine Arabinoside Influx and Nucleoside Transport Sites in Acute Leukemia

J. S. Wiley, S. P. Jones, W. H. Sawyer, and A. R. P. Paterson

Department of Haematology, Austin Hospital, Melbourne, Australia

The Russell Grimwade School of Biochemistry, University of Melbourne, Australia

McEachern Laboratory, University of Alberta, Edmonton, Canada

Find articles by Wiley, J. in: JCI | PubMed | Google Scholar

Department of Haematology, Austin Hospital, Melbourne, Australia

The Russell Grimwade School of Biochemistry, University of Melbourne, Australia

McEachern Laboratory, University of Alberta, Edmonton, Canada

Find articles by Jones, S. in: JCI | PubMed | Google Scholar

Department of Haematology, Austin Hospital, Melbourne, Australia

The Russell Grimwade School of Biochemistry, University of Melbourne, Australia

McEachern Laboratory, University of Alberta, Edmonton, Canada

Find articles by Sawyer, W. in: JCI | PubMed | Google Scholar

Department of Haematology, Austin Hospital, Melbourne, Australia

The Russell Grimwade School of Biochemistry, University of Melbourne, Australia

McEachern Laboratory, University of Alberta, Edmonton, Canada

Find articles by Paterson, A. in: JCI | PubMed | Google Scholar

Published February 1, 1982 - More info

Published in Volume 69, Issue 2 on February 1, 1982
J Clin Invest. 1982;69(2):479–489. https://doi.org/10.1172/JCI110472.
© 1982 The American Society for Clinical Investigation
Published February 1, 1982 - Version history
View PDF
Abstract

Although cytosine arabinoside (araC) can induce a remission in a majority of patients presenting with acute myeloblastic leukemia (AML), a minority fail to respond and moreover the drug has less effect in acute lymphoblastic leukemia (ALL). The carrier-mediated influx of araC into purified blasts from patients with AML, ALL, and acute undifferentiated leukemia (AUL) has been compared to that of normal lymphocytes and polymorphs. Blasts showed a larger mediated influx of araC than mature cells, since mean influxes for myeloblasts and lymphoblasts were 6- and 2.3-fold greater than polymorphs and lymphocytes, respectively. Also, the mean influx for myeloblasts was fourfold greater than the mean for lymphoblasts. The number of nucleoside transport sites was estimated for each cell type by measuring the equilibrium binding of [3H]nitrobenzylthioinosine (NBMPR), which inhibits nucleoside fluxes by binding with high affinity to specific sites on the transport mechanism. The mean binding site numbers for myeloblasts and lymphoblasts were 5- and 2.8-fold greater, respectively, than for the mature cells of the same maturation series. The mean number of NBMPR binding sites for myeloblasts was fourfold greater than for lymphoblasts. Patients with AUL were heterogeneous since blasts from some gave values within the myeloblastic range and others within the lymphoblastic range. The araC influx correlated closely with the number of NBMPR binding sites measured in the same cells on the same day. Transport parameters were measured on blasts from 15 patients with AML or AUL who were then treated with standard induction therapy containing araC. Eight patients entered complete remission, while seven failed therapy, among whom were the three patients with the lowest araC influx (<0.4 pmol/107 cells per min) and NBMPR binding (<3,000 sites/cell) for the treated group. In summary, myeloblasts have both higher araC transport rates and more nucleoside transport sites than lymphoblasts and this factor may contribute to the greater sensitivity of AML to this drug. AraC transport varied >10-fold between leukemic blasts and normal leukocytes, but transport capacity related directly to the number of nucleoside transport sites on the cell. Finally, low araC transport rates or few NBMPR binding sites on blasts were observed in a subset of patients with acute leukemia who failed to achieve remission with drug combinations containing araC.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 479
page 479
icon of scanned page 480
page 480
icon of scanned page 481
page 481
icon of scanned page 482
page 482
icon of scanned page 483
page 483
icon of scanned page 484
page 484
icon of scanned page 485
page 485
icon of scanned page 486
page 486
icon of scanned page 487
page 487
icon of scanned page 488
page 488
icon of scanned page 489
page 489
Version history
  • Version 1 (February 1, 1982): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts